Ra Pharmctl Inc (NASDAQ:RARX) – SunTrust Banks decreased their Q3 2017 earnings estimates for Ra Pharmctl in a research note issued to investors on Wednesday. SunTrust Banks analyst Y. Suneja now anticipates that the company will earn ($0.74) per share for the quarter, down from their previous forecast of ($0.52). SunTrust Banks also issued estimates for Ra Pharmctl’s Q4 2017 earnings at ($0.82) EPS, FY2017 earnings at ($2.63) EPS, FY2018 earnings at ($2.75) EPS and FY2019 earnings at ($3.00) EPS.

Ra Pharmctl (NASDAQ:RARX) last posted its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.06.

COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Estimate for Ra Pharmctl Inc Issued By SunTrust Banks (NASDAQ:RARX)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/14/q3-2017-earnings-estimate-for-ra-pharmctl-inc-issued-by-suntrust-banks-nasdaqrarx.html.

Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Ra Pharmctl from a “buy” rating to a “hold” rating in a research note on Thursday, May 25th. Jefferies Group LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Ra Pharmctl in a research note on Friday, July 14th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $19.00 target price on shares of Ra Pharmctl in a research note on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Ra Pharmctl currently has an average rating of “Buy” and a consensus price target of $27.00.

Shares of Ra Pharmctl (NASDAQ:RARX) opened at 13.73 on Monday. The firm’s market capitalization is $310.42 million. The firm has a 50-day moving average of $16.29 and a 200 day moving average of $20.32. Ra Pharmctl has a 12-month low of $12.05 and a 12-month high of $27.84.

In other news, major shareholder Bioventures Ltd Novartis sold 56,420 shares of the company’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $21.29, for a total value of $1,201,181.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 208,880 shares of company stock valued at $4,946,431. Company insiders own 14.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC raised its position in Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the last quarter. American International Group Inc. bought a new position in Ra Pharmctl during the first quarter valued at $102,000. Geode Capital Management LLC raised its position in Ra Pharmctl by 8.5% in the first quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares during the last quarter. Wells Fargo & Company MN raised its position in Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Ra Pharmctl by 87.8% in the second quarter. New York State Common Retirement Fund now owns 13,900 shares of the company’s stock valued at $260,000 after buying an additional 6,499 shares during the last quarter. Institutional investors own 62.40% of the company’s stock.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Earnings History and Estimates for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.